The effect of histone deacetylase inhibitors on the bone environment in multiple myeloma [ 2014 - 2021 ]

Also known as: HDACi and bone in Multiple myeloma

Research Grant

[Cite as]

Researchers: Dr Melissa Cantley (Principal investigator)

Brief description Multiple myeloma (MM) is an incurable hematological malignancy with 1,400 people diagnosed each year. Severe bone loss occurs in up to 90% of these patientssignificantly impacting on quality of life resulting in severe bone pain and bone lesions that fail to heal. This project proposes that a novel histone deacetylase inhibitor could provide an appropriate therapeutic strategy that inhibits tumor growth and prevents bone loss whilst also promoting bone repair.

Funding Amount $AUD 356,899.46

Funding Scheme Early Career Fellowships

Notes Peter Doherty Biomedical ECF

Click to explore relationships graph
Viewed: [[ro.stat.viewed]]